Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -117.65% is 181% below its 5-year average of -41.83%, near the low end of its 5-year range (-117.65%–-14.89%).
68.92% below its 12-month average of -69.65%.
Reported quarterly return on assets; no daily interpolation. Q1 FY2027 (2026-06-30): -27.64%.
RETURN ON ASSETS (ROA)
-117.65%
RETURN ON ASSETS (ROA) AVG TTM
-69.65%
RETURN ON ASSETS (ROA) AVG 3Y
-52.63%
RETURN ON ASSETS (ROA) AVG 5Y
-41.83%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-68.92%
CURRENT VS 3Y AVG
-123.56%
CURRENT VS 5Y AVG
-181.26%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-264.64%
vs the sector median at left
Replimune Group, Inc.
Market Cap
$1.11B
Return on Assets (ROA)
-117.65%
TTM Avg
-69.65%
3Y Avg
-52.63%
5Y Avg
-41.83%
Market Cap
$1.11B
Return on Assets (ROA)
-5.49%
TTM Avg
-16.57%
3Y Avg
-16.38%
5Y Avg
-11.43%
Market Cap
$1.10B
Return on Assets (ROA)
0.81%
TTM Avg
-17.43%
3Y Avg
-5.68%
5Y Avg
0.08%
Market Cap
$1.13B
Return on Assets (ROA)
-57.23%
TTM Avg
-57.23%
3Y Avg
-57.23%
5Y Avg
-57.23%
Market Cap
$1.13B
Return on Assets (ROA)
-8.93%
TTM Avg
-2.89%
3Y Avg
-5.64%
5Y Avg
-7.78%
Market Cap
$1.10B
Return on Assets (ROA)
-50.25%
TTM Avg
-43.65%
3Y Avg
-37.07%
5Y Avg
-37.07%
Market Cap
$1.13B
Return on Assets (ROA)
0.69%
TTM Avg
1.67%
3Y Avg
0.18%
5Y Avg
-3.47%
Market Cap
$1.09B
Return on Assets (ROA)
-3.98%
TTM Avg
-7.05%
3Y Avg
-9.66%
5Y Avg
-6.44%
Market Cap
$1.09B
Return on Assets (ROA)
-36.19%
TTM Avg
-21.98%
3Y Avg
-157.70%
5Y Avg
-157.70%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Replimune Group, Inc. (REPL) | $1.11B | -117.65% | -69.65% | -52.63% | -41.83% |
| Tandem Diabetes Care, Inc. (TNDM)vs › | $1.11B | -5.49% | -16.57% | -16.38% | -11.43% |
| STAAR Surgical Company (STAA)vs › | $1.10B | 0.81% | -17.43% | -5.68% | 0.08% |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.13B | -57.23% | -57.23% | -57.23% | -57.23% |
| Harrow Health, Inc. (HROW)vs › | $1.13B | -8.93% | -2.89% | -5.64% | -7.78% |
| First Tracks Biotherapeutics Inc (TRAX)vs › | $1.10B | -50.25% | -43.65% | -37.07% | -37.07% |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.13B | 0.69% | 1.67% | 0.18% | -3.47% |
| OPKO Health, Inc. (OPK)vs › | $1.09B | -3.98% | -7.05% | -9.66% | -6.44% |
| Bicara Therapeutics Inc. Common Stock (BCAX)vs › | $1.09B | -36.19% | -21.98% | -157.70% | -157.70% |
| IRadimed Corporation (IRMD)vs › | $1.08B | 20.05% | 20.12% | 18.47% | 14.51% |
ROA
-117.7%
ROE
-281.1%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2026-03-31 | -94.45% |
| 2025-03-31 | -44.85% |
| 2024-03-31 | -44.25% |
| 2023-03-31 | -26.95% |
| 2022-03-31 | -25.59% |
| 2021-03-31 | -14.89% |
| 2020-03-31 | -22.48% |
| 2019-03-31 | -19.98% |
| 2018-03-31 | -30.24% |
| 2017-03-31 | -33.76% |
